DE-LYCRA
24.4.2024 17:01:33 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel industry, announced the launch of a revolutionary new targeted shaping innovation for stretch denim at a press conference at Kingpins Amsterdam today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424493653/en/
The LYCRA Company launches a revolutionary new targeted shaping innovation for stretch denim at Kingpins Amsterdam Spring 2024: LYCRA FitSense® denim technology. (Photo: Business Wire)
LYCRA FitSense® denim technology is a shaping technology engineered to provide a unique fit solution to consumers of all body types and shapes. Its advanced shaping effect delivers targeted support to common trouble spots that can impact garment fit, such as the tummy and waist, thighs and rear, offering a customizable fit solution that is a breakthrough for the denim industry.
“Targeted support is engineered into stretch jeans using our technology, new fabric construction, and precision garment making,” said Ebru Ozaydin, The LYCRA Company’s global strategic marketing director for denim, wovens, and ready-to-wear. “Our innovative solution is discreet and invisible, and jeans retain the authentic denim look and feel consumers love.”
Designers working for brands and garment makers will be able to take their craft to the next level by choosing where to shape, support, and lift, delivering a customized fit experience that will help consumers look and feel great in their jeans. This innovation also offers the potential to increase consumer satisfaction and reduce costly returns related to poor fit.
“The LYCRA® brand has consistently redefined what is possible, and our technologies continue to reshape the apparel industry,” said Steve Stewart, chief brand & innovation officer. “We’re thrilled to bring LYCRA FitSense® denim technology to market and look forward to showcasing it at Kingpins China in May and Kingpins New York in July.”
For the third consecutive year, the LYCRA® brand has teamed up with the House of Denim Foundation and Jean School students to mount the exhibition “Stretch Yourself #3: Denim of the Future, Designed by Gen Z.” Once again, talented student designers have created inspiring silhouettes that feature innovative fabrics from leading mills and powered by The LYCRA Company’s technologies.
Kingpins visitors can also learn more about the development of bio-derived LYCRA® fiber made with QIRA®. The LYCRA Company has teamed up with Qore®, the maker of QIRA®, to enable the world’s first large-scale commercial production of renewable elastane. Available in early 2025, this sustainable product will use field corn to reduce the carbon footprint of LYCRA® fiber by up to 44 percent* and is expected to offer equivalent performance.
The LYCRA® brand is also celebrating 20 years of Kingpins Shows, including 10 years in Amsterdam, by sponsoring a happy hour at the end of the first day. DJ Red Planet will provide the soundtrack as memorable moments in the iconic brand's 65-year history flash on monitors. Opening remarks will recognize the elastane brand's status as the longest-standing sponsor of the show and the strong bond both companies share.
"A sure sign of success in life is who chooses to accompany you on the journey,” said Andrew Olah, Founder and CEO of Kingpins. “The LYCRA Company has been an amazing partner to so many in the jeans business and Kingpins has gained so much by our close relationship over two decades.”
To learn more about new LYCRA FitSense® denim technology, visit The LYCRA Company in the blue zone stand 11 at Kingpins Amsterdam, or lycra.com.
*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll US Consulting, Inc.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns the leading consumer brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL®. Headquartered in Wilmington, Delaware, U.S., The LYCRA Company is recognized worldwide for its sustainable products, technical expertise, and marketing support. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
LYCRA® and LYCRA FitSense® are trademarks of The LYCRA Company.
Qore® and QIRA® are trademarks of Qore® LLC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424493653/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom